复星医药 - Financials

复星医药 — Financial Statements

Annual Quarterly

5 10 All

Income Statement

Balance Sheet

Cash Flow

Line Item	FY 2024Dec 31, 2024	FY 2023Dec 31, 2023	FY 2022Dec 31, 2022	FY 2021Dec 31, 2021	FY 2020Dec 31, 2020
+Revenue	41.1B	41.4B	44.0B	39.0B	30.3B
Revenue Growth %	-0.8%	-5.8%	12.7%	28.7%	--
Total Revenue	41.1B	41.4B	44.0B	39.0B	30.3B
Cost Of Revenue	21.4B	21.6B	23.2B	20.2B	13.7B
+Gross Profit	19.7B	19.8B	20.8B	18.8B	16.6B
Gross Margin %	48.0%	47.8%	47.3%	48.1%	54.7%
Total Operating Cost	39.6B	41.6B	41.7B	38.0B	28.8B
Selling Expenses	8.7B	9.7B	9.2B	9.1B	8.2B
Admin Expenses	4.3B	4.4B	3.8B	3.2B	3.0B
Rd Expenses	3.6B	4.3B	4.3B	3.8B	2.8B
Finance Expenses	1.1B	984.0M	647.0M	464.0M	724.0M
+Operating Income	4.2B	3.3B	4.7B	6.3B	4.7B
Operating Margin %	10.3%	8.0%	10.6%	16.2%	15.6%
Non Operating Income	58.9M	57.1M	35.5M	28.7M	23.1M
Non Operating Expenses	135.0M	100.0M	118.0M	289.0M	66.4M
Investment Income	2.1B	3.5B	4.4B	4.6B	2.3B
Fair Value Change Income	-116.0M	-427.0M	-2.5B	352.0M	579.0M
Asset Disposal Income	371.0M	5.6M	126.0M	-15.4M	5.7M
Asset Impairment Loss	96.6M	220.0M	272.0M	830.0M	148.0M
Other Income	423.0M	464.0M	384.0M	328.0M	394.0M
Income Before Tax	4.2B	3.3B	4.6B	6.0B	4.7B
Income Tax	657.0M	370.0M	627.0M	1.1B	738.0M
+Net Income	3.5B	2.9B	3.9B	5.0B	3.9B
Net Margin %	8.6%	7.0%	9.0%	12.8%	13.0%
Net Income Attributable	2.8B	2.4B	3.7B	4.7B	3.7B
Minority Interest	743.0M	509.0M	217.0M	248.0M	277.0M
Eps Basic	1.04	0.89	1.43	1.85	1.43
Eps Diluted	1.04	0.89	1.43	1.85	1.43

Line Item	FY 2024Dec 31, 2024	FY 2023Dec 31, 2023	FY 2022Dec 31, 2022	FY 2021Dec 31, 2021	FY 2020Dec 31, 2020
Cash And Equivalents	13.5B	13.7B	16.2B	10.3B	10.0B
Trading Financial Assets	2.6B	1.9B	929.0M	4.2B	2.0B
Accounts Receivable	8.0B	7.6B	7.6B	6.0B	4.6B
Notes Receivable	72.4M	24.5M	24.8M	16.2M	242.0M
Notes And Accounts Receivable	8.0B	7.7B	7.6B	6.0B	4.8B
Prepayments	865.0M	885.0M	1.6B	1.7B	1.5B
Inventory	7.3B	7.5B	6.9B	5.5B	5.2B
Total Current Assets	34.5B	33.8B	35.3B	30.4B	25.1B
Long Term Equity Investment	24.7B	23.9B	23.1B	22.7B	22.3B
Fixed Assets	--	15.1B	10.3B	8.9B	8.1B
Fixed Assets Total	17.4B	15.1B	10.3B	8.9B	8.1B
Construction In Progress	--	4.9B	4.9B	3.6B	4.1B
Construction In Progress Total	3.4B	4.9B	4.9B	3.6B	4.1B
Intangible Assets	14.5B	13.5B	12.5B	10.3B	8.7B
Long Term Deferred Expenses	1.4B	779.0M	554.0M	475.0M	323.0M
Total Non Current Assets	83.0B	79.7B	71.9B	62.9B	58.6B
Total Assets	117.5B	113.5B	107.2B	93.3B	83.7B
Short Term Borrowings	18.7B	14.7B	11.9B	9.4B	7.9B
Accounts Payable	5.4B	5.5B	5.4B	4.5B	2.9B
Advance Receipts	--	--	--	--	--
Contract Liabilities	1.2B	1.2B	1.5B	1.2B	1.0B
Total Current Liabilities	37.5B	33.8B	33.3B	29.3B	24.9B
Long Term Borrowings	10.2B	13.5B	11.6B	6.7B	7.1B
Total Non Current Liabilities	20.1B	23.1B	19.8B	15.6B	12.8B
Total Liabilities	57.5B	56.9B	53.1B	44.9B	37.7B
Paid In Capital	2.7B	2.7B	2.7B	2.6B	2.6B
Capital Reserve	16.6B	16.9B	17.0B	14.0B	15.1B
Surplus Reserve	3.0B	3.0B	3.0B	2.8B	2.7B
Retained Earnings	26.6B	24.5B	23.2B	21.0B	17.5B
Minority Equity	12.7B	10.9B	9.5B	9.2B	9.0B
Equity Attributable	47.3B	45.7B	44.6B	39.2B	37.0B
Total Equity	59.9B	56.6B	54.1B	48.4B	46.0B

Line Item	FY 2024Dec 31, 2024	FY 2023Dec 31, 2023	FY 2022Dec 31, 2022	FY 2021Dec 31, 2021	FY 2020Dec 31, 2020
Cash From Sales	41.0B	42.4B	44.4B	38.4B	32.0B
Tax Refunds Received	482.0M	442.0M	708.0M	434.0M	289.0M
Total Operating Cash Inflow	43.2B	44.4B	46.1B	39.4B	32.9B
Cash Paid For Goods	15.1B	17.0B	20.5B	16.7B	14.6B
Cash Paid To Employees	11.1B	10.6B	9.2B	7.1B	5.3B
Taxes Paid	2.6B	2.8B	2.3B	2.3B	2.5B
Total Operating Cash Outflow	38.7B	41.0B	41.9B	35.5B	30.4B
Operating Cash Flow	4.5B	3.4B	4.2B	3.9B	2.6B
Total Investing Cash Inflow	2.4B	3.8B	6.5B	4.6B	2.2B
Total Investing Cash Outflow	6.0B	7.6B	10.5B	8.5B	6.9B
Investing Cash Flow	-3.6B	-3.8B	-4.1B	-3.9B	-4.7B
Cash From Borrowings	30.9B	23.2B	30.0B	29.2B	18.0B
Dividends And Interest Paid	2.5B	2.7B	2.5B	2.2B	2.2B
Debt Repayments	30.5B	21.1B	26.3B	27.4B	15.7B
Total Financing Cash Inflow	33.4B	23.6B	35.3B	30.5B	21.7B
Total Financing Cash Outflow	34.4B	24.9B	30.9B	31.3B	20.2B
Financing Cash Flow	-1.0B	-1.3B	4.4B	-819.0M	1.5B
Net Change In Cash	-111.0M	-1.7B	4.7B	-874.0M	-959.0M
Ending Cash Balance	9.4B	9.5B	11.2B	6.5B	7.3B
Capex	4.4B	5.3B	5.9B	5.0B	4.4B